Barbara C. Fullerton, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Evoked Potentials, Auditory, Brain Stem | 8 | 2005 | 253 | 0.590 |
Why?
|
| Photons | 7 | 2018 | 586 | 0.480 |
Why?
|
| Auditory Pathways | 6 | 2005 | 224 | 0.360 |
Why?
|
| Radiation Injuries | 6 | 2021 | 1286 | 0.320 |
Why?
|
| Cochlear Nucleus | 2 | 2005 | 58 | 0.310 |
Why?
|
| Inferior Colliculi | 3 | 2005 | 62 | 0.310 |
Why?
|
| Radiotherapy, Conformal | 6 | 2013 | 576 | 0.300 |
Why?
|
| Brain Stem | 10 | 2000 | 811 | 0.290 |
Why?
|
| Olivary Nucleus | 2 | 2005 | 132 | 0.290 |
Why?
|
| Auditory Cortex | 2 | 2007 | 294 | 0.290 |
Why?
|
| Meningioma | 3 | 2019 | 1068 | 0.280 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 9 | 2021 | 1407 | 0.280 |
Why?
|
| Meningeal Neoplasms | 3 | 2019 | 1073 | 0.280 |
Why?
|
| Relative Biological Effectiveness | 2 | 2021 | 362 | 0.230 |
Why?
|
| Temporal Lobe | 2 | 2007 | 1621 | 0.230 |
Why?
|
| Radiotherapy, Intensity-Modulated | 4 | 2021 | 734 | 0.210 |
Why?
|
| Cranial Irradiation | 3 | 2019 | 433 | 0.210 |
Why?
|
| Radiotherapy Dosage | 11 | 2021 | 2911 | 0.190 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2019 | 49 | 0.190 |
Why?
|
| Glioma | 3 | 2019 | 3015 | 0.180 |
Why?
|
| Neurosecretory Systems | 1 | 2019 | 237 | 0.170 |
Why?
|
| Optic Nerve | 2 | 2018 | 549 | 0.170 |
Why?
|
| Hypopituitarism | 1 | 2019 | 249 | 0.170 |
Why?
|
| Chondrosarcoma | 5 | 2018 | 294 | 0.150 |
Why?
|
| Optic Nerve Diseases | 1 | 2018 | 313 | 0.150 |
Why?
|
| Supratentorial Neoplasms | 2 | 2013 | 152 | 0.150 |
Why?
|
| Cerebellar Neoplasms | 2 | 2013 | 574 | 0.140 |
Why?
|
| Brain Neoplasms | 5 | 2019 | 8385 | 0.140 |
Why?
|
| Organs at Risk | 2 | 2018 | 314 | 0.140 |
Why?
|
| Medulloblastoma | 2 | 2013 | 679 | 0.140 |
Why?
|
| Auditory Perception | 6 | 1998 | 505 | 0.130 |
Why?
|
| Pituitary Neoplasms | 1 | 2021 | 1202 | 0.130 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2013 | 134 | 0.120 |
Why?
|
| Protons | 2 | 2012 | 953 | 0.120 |
Why?
|
| Skull Base Neoplasms | 3 | 2001 | 237 | 0.120 |
Why?
|
| Chordoma | 4 | 2018 | 379 | 0.120 |
Why?
|
| Cats | 4 | 1996 | 1059 | 0.110 |
Why?
|
| Rhabdoid Tumor | 1 | 2013 | 205 | 0.110 |
Why?
|
| Pituitary Gland | 3 | 2019 | 659 | 0.110 |
Why?
|
| Teratoma | 1 | 2013 | 379 | 0.110 |
Why?
|
| Memory Disorders | 1 | 2018 | 1109 | 0.110 |
Why?
|
| Radiation Tolerance | 2 | 2018 | 556 | 0.100 |
Why?
|
| Pons | 4 | 2000 | 263 | 0.090 |
Why?
|
| Multiple Sclerosis | 6 | 2000 | 2676 | 0.090 |
Why?
|
| Postmortem Changes | 1 | 2007 | 131 | 0.090 |
Why?
|
| Sound Localization | 2 | 2000 | 56 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2017 | 8158 | 0.090 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2012 | 601 | 0.080 |
Why?
|
| Macaca | 1 | 2007 | 451 | 0.080 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2010 | 427 | 0.080 |
Why?
|
| Cauda Equina | 1 | 2005 | 49 | 0.080 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2013 | 767 | 0.080 |
Why?
|
| Ependymoma | 1 | 2008 | 304 | 0.070 |
Why?
|
| Acoustic Stimulation | 4 | 2005 | 1153 | 0.070 |
Why?
|
| Hippocampus | 1 | 2018 | 3503 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 954 | 0.070 |
Why?
|
| Skull Neoplasms | 2 | 2018 | 190 | 0.070 |
Why?
|
| Evoked Potentials, Auditory | 1 | 1987 | 515 | 0.070 |
Why?
|
| Noise | 1 | 2005 | 251 | 0.060 |
Why?
|
| Staining and Labeling | 1 | 2007 | 1149 | 0.060 |
Why?
|
| Rhabdomyosarcoma | 1 | 2005 | 368 | 0.060 |
Why?
|
| Male | 29 | 2021 | 343917 | 0.060 |
Why?
|
| Orbital Neoplasms | 1 | 2005 | 320 | 0.060 |
Why?
|
| Functional Laterality | 2 | 2007 | 2349 | 0.060 |
Why?
|
| Cognition | 2 | 2018 | 5290 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2005 | 32095 | 0.060 |
Why?
|
| Adult | 21 | 2021 | 206295 | 0.060 |
Why?
|
| Female | 28 | 2021 | 365199 | 0.050 |
Why?
|
| Radiometry | 2 | 2018 | 812 | 0.050 |
Why?
|
| Ear | 1 | 2000 | 176 | 0.050 |
Why?
|
| Brain | 5 | 2021 | 23362 | 0.050 |
Why?
|
| Moyamoya Disease | 1 | 2021 | 185 | 0.050 |
Why?
|
| Disease-Free Survival | 3 | 2017 | 7080 | 0.050 |
Why?
|
| Humans | 35 | 2021 | 660731 | 0.050 |
Why?
|
| Infratentorial Neoplasms | 2 | 2013 | 98 | 0.050 |
Why?
|
| Craniopharyngioma | 1 | 2021 | 261 | 0.050 |
Why?
|
| Thyroid Function Tests | 1 | 2019 | 271 | 0.050 |
Why?
|
| Child, Preschool | 7 | 2021 | 40276 | 0.050 |
Why?
|
| Nausea | 1 | 2021 | 654 | 0.050 |
Why?
|
| Brain Mapping | 2 | 2007 | 6265 | 0.040 |
Why?
|
| Vomiting | 1 | 2021 | 630 | 0.040 |
Why?
|
| Kainic Acid | 1 | 1996 | 200 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 416 | 0.040 |
Why?
|
| Prospective Studies | 6 | 2021 | 46949 | 0.040 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 1996 | 155 | 0.040 |
Why?
|
| Treatment Outcome | 6 | 2021 | 59149 | 0.040 |
Why?
|
| Mental Processes | 1 | 1997 | 246 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2008 | 1002 | 0.040 |
Why?
|
| Adolescent | 10 | 2021 | 82796 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2021 | 1301 | 0.040 |
Why?
|
| Hypothalamus | 1 | 2001 | 1081 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 1901 | 0.040 |
Why?
|
| Aged | 10 | 2019 | 156937 | 0.040 |
Why?
|
| Infant | 5 | 2021 | 33054 | 0.040 |
Why?
|
| Cerebral Infarction | 1 | 2000 | 1007 | 0.040 |
Why?
|
| Middle Aged | 16 | 2019 | 210747 | 0.040 |
Why?
|
| Echo-Planar Imaging | 1 | 1998 | 597 | 0.030 |
Why?
|
| Fatigue | 1 | 2021 | 1345 | 0.030 |
Why?
|
| Vision Disorders | 1 | 2021 | 963 | 0.030 |
Why?
|
| Headache | 1 | 2021 | 1016 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2005 | 12724 | 0.030 |
Why?
|
| Retrospective Studies | 6 | 2021 | 63232 | 0.030 |
Why?
|
| Child | 7 | 2021 | 68786 | 0.030 |
Why?
|
| Chondroma | 1 | 1992 | 60 | 0.030 |
Why?
|
| Cranial Nerves | 1 | 1992 | 94 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 1 | 1998 | 1485 | 0.030 |
Why?
|
| Endocrine System Diseases | 1 | 2013 | 242 | 0.030 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1992 | 285 | 0.030 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 38875 | 0.030 |
Why?
|
| Germinoma | 1 | 2010 | 122 | 0.030 |
Why?
|
| Young Adult | 4 | 2021 | 54078 | 0.020 |
Why?
|
| Cochlear Nerve | 1 | 1990 | 182 | 0.020 |
Why?
|
| Cochlea | 2 | 2012 | 721 | 0.020 |
Why?
|
| Memory | 1 | 2018 | 2091 | 0.020 |
Why?
|
| Reaction Time | 3 | 1998 | 2114 | 0.020 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2013 | 714 | 0.020 |
Why?
|
| Quality of Life | 2 | 2019 | 10147 | 0.020 |
Why?
|
| Electrophysiology | 3 | 1996 | 1389 | 0.020 |
Why?
|
| Survival Rate | 3 | 2010 | 13249 | 0.020 |
Why?
|
| Body Height | 1 | 2013 | 1589 | 0.020 |
Why?
|
| Stapedius | 1 | 1985 | 25 | 0.020 |
Why?
|
| Actuarial Analysis | 1 | 2005 | 412 | 0.020 |
Why?
|
| Psychoacoustics | 2 | 1995 | 59 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 6698 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 3385 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 1998 | 3055 | 0.020 |
Why?
|
| Prognosis | 2 | 2019 | 28027 | 0.020 |
Why?
|
| Animals | 7 | 2007 | 168501 | 0.020 |
Why?
|
| Auditory Threshold | 2 | 1995 | 347 | 0.020 |
Why?
|
| Cause of Death | 1 | 2013 | 3464 | 0.020 |
Why?
|
| Facial Nerve | 1 | 1985 | 269 | 0.020 |
Why?
|
| Species Specificity | 1 | 1987 | 2663 | 0.020 |
Why?
|
| Disease Progression | 1 | 2019 | 12859 | 0.020 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2005 | 340 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2008 | 2647 | 0.010 |
Why?
|
| Neurons | 2 | 1996 | 9179 | 0.010 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 57680 | 0.010 |
Why?
|
| Incidence | 1 | 2018 | 19739 | 0.010 |
Why?
|
| Hyperprolactinemia | 1 | 2001 | 127 | 0.010 |
Why?
|
| Fetal Hypoxia | 1 | 1979 | 30 | 0.010 |
Why?
|
| Muscles | 1 | 1985 | 1591 | 0.010 |
Why?
|
| Motor Neurons | 1 | 1985 | 806 | 0.010 |
Why?
|
| Dichotic Listening Tests | 1 | 1998 | 22 | 0.010 |
Why?
|
| Asphyxia Neonatorum | 1 | 1979 | 99 | 0.010 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1987 | 1588 | 0.010 |
Why?
|
| Risk | 1 | 2012 | 9826 | 0.010 |
Why?
|
| Spinal Neoplasms | 1 | 2005 | 727 | 0.010 |
Why?
|
| Discrimination Learning | 1 | 1979 | 290 | 0.010 |
Why?
|
| Nissl Bodies | 1 | 1996 | 20 | 0.010 |
Why?
|
| Neuropsychology | 1 | 1997 | 82 | 0.010 |
Why?
|
| Hypothyroidism | 1 | 2001 | 624 | 0.010 |
Why?
|
| Stroke | 1 | 2017 | 8397 | 0.010 |
Why?
|
| Hypogonadism | 1 | 2001 | 713 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 6754 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2013 | 23295 | 0.010 |
Why?
|
| Time Factors | 1 | 2017 | 41842 | 0.010 |
Why?
|
| Audiometry | 1 | 1995 | 238 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2004 | 4652 | 0.010 |
Why?
|
| Axons | 2 | 1996 | 1672 | 0.010 |
Why?
|
| Cranial Nerve Injuries | 1 | 1992 | 26 | 0.010 |
Why?
|
| Risk Factors | 1 | 2018 | 66887 | 0.010 |
Why?
|
| Speech Perception | 1 | 1994 | 402 | 0.010 |
Why?
|
| Reference Values | 1 | 1998 | 5150 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 13598 | 0.010 |
Why?
|
| Cricetinae | 1 | 1993 | 2640 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 1997 | 1932 | 0.010 |
Why?
|
| Learning | 1 | 1997 | 1461 | 0.010 |
Why?
|
| Heart Rate | 1 | 1998 | 4166 | 0.000 |
Why?
|
| Models, Neurological | 1 | 1995 | 1766 | 0.000 |
Why?
|
| Chorda Tympani Nerve | 1 | 1985 | 15 | 0.000 |
Why?
|
| Combined Modality Therapy | 1 | 1998 | 9035 | 0.000 |
Why?
|
| Nerve Endings | 1 | 1983 | 114 | 0.000 |
Why?
|
| Vagus Nerve | 1 | 1985 | 441 | 0.000 |
Why?
|
| Cell Count | 1 | 1985 | 1989 | 0.000 |
Why?
|
| Nerve Fibers | 1 | 1983 | 696 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1983 | 3050 | 0.000 |
Why?
|
| Haplorhini | 1 | 1979 | 592 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2001 | 20102 | 0.000 |
Why?
|
| Synapses | 1 | 1983 | 1645 | 0.000 |
Why?
|
| Evoked Potentials | 1 | 1979 | 1006 | 0.000 |
Why?
|
| Macaca mulatta | 1 | 1979 | 2365 | 0.000 |
Why?
|
| Pregnancy | 1 | 1979 | 24677 | 0.000 |
Why?
|